---
slug: anticoagulants-bleeding-scd
title: Direct Oral Anticoagulants in Sickle Cell Disease
author: Hants Williams
author_url: https://github.com/hantswilliams
author_title: Healthcare Informatics Researcher
author_image_url: /img/hants.jpeg
date: 2017-12-01
tags: [sickle cell disease, anticoagulants, venous thromboembolism, bleeding risk]
---

# Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism is Associated with a Significant Decrease in Incidence of Bleeding

## Abstract

This research evaluates the safety profile of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism, focusing on bleeding incidence rates compared to traditional anticoagulation methods.

<!--truncate-->

## Publication Information

Published in Blood (2017)  
Volume: 130, Page: 978

## Overview

The study demonstrates the improved safety profile of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism, specifically highlighting the reduced incidence of bleeding complications.

[Full text available via Blood Journal]

## Citation

Patel, A., Williams, H., Baer, M. R., Zimrin, A. B., & Law, J. Y. (2017). Use of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism is associated with a significant decrease in incidence of bleeding. Blood, 130, 978.
